- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients | 1 | Oslo Børs | ||
| ONCOINVENT Aktie jetzt für 0€ handeln | |||||
| 05.03. | Oncoinvent ASA: Mandatory notification of trade | - | Oslo Børs | ||
| 27.02. | Oncoinvent ASA: Fourth Quarter 2024 Update and Results | 1 | Cision News | ||
| 27.02. | Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients | 1 | Cision News | ||
| 26.02. | Oncoinvent ASA: Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference | 230 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference... ► Artikel lesen | |
| 20.02. | Oncoinvent ASA: Invitation to Result Presentation Q4 2024 | 365 | PR Newswire | OSLO, Norway, Feb. 20, 2025 /PRNewswire/ -- In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:
Thursday... ► Artikel lesen | |
| 19.02. | Oncoinvent ASA to present at various conferences | - | Oslo Børs | ||
| 18.02. | Oncoinvent ASA: Registration of new share capital | - | Oslo Børs | ||
| 06.02. | Oncoinvent ASA: Last day of the subscription period in the subsequent offering | 1 | Oslo Børs | ||
| 04.02. | Oncoinvent ASA: Grant of share options - mandatory notification of trade | - | Oslo Børs | ||
| 23.01. | Oncoinvent ASA: Commencement of subscription period for subsequent offering | 2 | Oslo Børs | ||
| 22.01. | Oncoinvent ASA: Key information relating to subsequent offering | - | Oslo Børs | ||
| 22.01. | Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering | - | Oslo Børs | ||
| 10.01. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 10.01.2025 | 571 | Xetra Newsboard | The following instruments on XETRA do have their first trading 10.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.01.2025
Aktien
1 ES06445809T5 Iberdrola S.A. BZR
2... ► Artikel lesen | |
| 18.12.24 | Oncoinvent ASA: Financial calendar | 2 | Oslo Børs | ||
| 13.12.24 | Oncoinvent lists on Euronext Growth Oslo | 3 | Euronext | ||
| 13.12.24 | Oncoinvent ASA: First day of trading on Euronext Growth Oslo and publication of information document | 3 | Oslo Børs | ||
| 12.12.24 | Oncoinvent ASA: Notifiable transactions in connection with Private Placement | 1 | Oslo Børs | ||
| 05.12.24 | Oncoinvent ASA announces oversubscribed private placement | 385 | PR Newswire | OSLO, Norway, Dec. 5, 2024 /PRNewswire/ -- Oncoinvent ASA ('Oncoinvent' or the 'Company') is pleased to announce that it has today successfully completed the bookbuilding process for a private... ► Artikel lesen | |
| 04.12.24 | Oncoinvent ASA: Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities | 299 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has entered into an agreement with ARTBIO, a clinical-stage radiopharmaceutical... ► Artikel lesen |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 27,350 | +8,49 % | Summit Therapeutics retains $32 target from JMP | ||
| QIAGEN | 36,900 | +2,56 % | Qiagen will 2026 mit drei neuen Laborgeräten an den Markt gehen | DJ Qiagen will 2026 mit drei neuen Laborgeräten an den Markt gehen
DOW JONES--Qiagen will im nächsten Jahr drei neue Probenvorbereitungsgeräte für die Laborautomatisierung auf den Markt bringen.... ► Artikel lesen | |
| TEMPUS AI | 43,170 | +5,47 % | Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence... ► Artikel lesen | |
| EVOTEC | 6,834 | +6,85 % | Evotec Aktie: Unterstützung hält, Chancen wachsen | Die Evotec Aktie konnte sich zu Wochenbeginn spürbar erholen. Nach einem gescheiterten Anlauf auf die 20-Tage-Linie und dem Rücksetzer am Freitag legte der Kurs am Montag auf XETRA um fast acht Prozent... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 29,450 | +3,33 % | Avidity Biosciences Inc Aktie: Routinebericht des Unternehmens | Avidity Biosciences hat die Rekrutierung für die Biomarker-Kohorte der Phase-1/2-FORTITUDE-Studie für Delpacibart Braxlosiran (Del-Brax) abgeschlossen. Diese Studie zielt auf Patienten mit fazioskapulohumeraler... ► Artikel lesen | |
| JANUX THERAPEUTICS | 30,010 | +2,53 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| CG ONCOLOGY | 20,480 | +0,39 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| BIONTECH | 91,20 | +6,60 % | Irrer Börsengang: BioNTech-Partner DualityBio explodiert am ersten Handelstag | Die Börse in Hongkong ist seit dem heutigen Mittwoch um ein Biotech-Unternehmen reicher. Duality Biotherapeutics (DualityBio) hat einen furiosen Start auf das Parkett gezaubert - nicht zuletzt dank... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 28,800 | +6,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader | Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 40,485 | +9,24 % | Barclays maintains SpringWorks stock at Overweight, $63 target | ||
| ARCELLX | 63,12 | +3,59 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,250 | +10,06 % | Why Verve Therapeutics Zoomed 40% Higher This Week | ||
| ADMA BIOLOGICS | 21,410 | +9,01 % | Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? | ||
| ZENTALIS PHARMACEUTICALS | 1,470 | +7,69 % | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,210 | -0,23 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen |
ONCOINVENT ASA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,97 % bei einem Aktienkurs von 0,125 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOINVENT ASA finden Sie auf Wallstreet Online.
